{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:27:59Z","timestamp":1785871679123,"version":"3.56.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Hip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-\u03b1 inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-\u03b1 inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p &amp;lt; 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-\u03b1 inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-\u03b1 inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 \u00b1 10.37 <jats:italic>vs.<\/jats:italic> 20.59 \u00b1 9.41, p &amp;lt; 0.001); the control group only had slight improvement (p &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>TNF-\u03b1 inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-\u03b1 in SpA patients with hip involvement to help guide targeted treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.740980","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T07:39:09Z","timestamp":1632901149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Clinical and MRI Effect of TNF-\u03b1 Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Kui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minwen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key382","article-title":"High Prevalence of Hip Involvement and Decrease in Inflammatory Ultrasound Lesions During Tumour Necrosis Factor-Alpha Blocking Therapy in Ankylosing Spondylitis","volume":"58","author":"Wink","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/rheumatology\/kep174","article-title":"Hip Involvement in Ankylosing Spondylitis: Epidemiology and Risk Factors Associated With Hip Replacement Surgery","volume":"49","author":"Vander","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2278-3","article-title":"Management of Hip Involvement in Ankylosing Spondylitis","volume":"32","author":"Guan","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21878","article-title":"Functional Limitations Due to Axial and Peripheral Joint Impairments in Patients With Ankylosing Spondylitis: Are Focused Measures More Informative","volume":"65","author":"Bethi","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283620e04","article-title":"Hip Disease in Ankylosing Spondylitis","volume":"25","author":"Vander","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.05.021","article-title":"Associated Risk Factors With Worse Functional Prognosis and Hip Replacement Surgery in Ankylosing Spondylitis","volume":"79","author":"Hamdi","year":"2012","journal-title":"Joint Bone Spine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21907","article-title":"Immunohistochemical Analysis of Hip Arthritis in Ankylosing Spondylitis: Evaluation of the Bone-Cartilage Interface and Subchondral Bone Marrow","volume":"54","author":"Appel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20160566","DOI":"10.1259\/bjr.20160566","article-title":"The Application of T2W SPIR-FLAIR in the Diagnosis of Hip Synovitis in Patients With Spondyloarthritis","volume":"89","author":"Huang","year":"2016","journal-title":"Br J Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181159","article-title":"Whole-Body Magnetic Resonance Imaging Inflammation in Peripheral Joints and Entheses in Axial Spondyloarthritis: Distribution and Changes During Adalimumab Treatment","volume":"47","author":"Krabbe","year":"2020","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131083","article-title":"Preliminary Validation of 2 Magnetic Resonance Image Scoring Systems for Osteoarthritis of the Hip According to the OMERACT Filter","volume":"41","author":"Maksymowych","year":"2014","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13451","article-title":"Application and Preliminary Validation of the Hip Inflammation MRI Scoring System (HIMRISS) in Spondyloarthritis","volume":"22","author":"Zheng","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14956.1","article-title":"Recent Advances in Ankylosing Spondylitis: Understanding the Disease and Management","volume-title":"F1000Res","author":"Garcia-Montoya","year":"2018"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR Axial Spondyloarthritis Treatment Recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1153232","article-title":"Early-Stage Hip Involvement in Patients With Ankylosing Spondylitis: A Chinese Study Based on Magnetic Resonance Imaging","volume":"26","author":"Chen","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A Tailored Approach to Reduce Dose of Anti-TNF Drugs may be Equally Effective, But Substantially Less Costly Than Standard Dosing in Patients With Ankylosing Spondylitis Over 1 Year: A Propensity Score-Matched Cohort Study","volume":"75","author":"Zavada","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1330419","article-title":"Comparison of Drug Survival and Clinical Outcome in Patients With Ankylosing Spondylitis Treated With Etanercept or Adalimumab","volume":"47","author":"Ruwaard","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11926-020-00930-7","article-title":"Hip and Shoulder Involvement and Their Management in Axial Spondyloarthritis: A Current Review","volume":"22","author":"Lopez-Medina","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2263-x","article-title":"Absence of Radiographic Progression of Hip Arthritis During Infliximab Treatment for Ankylosing Spondylitis","volume":"32","author":"Konsta","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"The Development of Assessment of SpondyloArthritis International Society Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of Diagnostic Criteria for Ankylosing Spondylitis. A Proposal for Modification of the New York Criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3693-7","article-title":"Indirect Comparisons of the Efficacy of Biological Agents in Patients With Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis","volume":"36","author":"Ungprasert","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B22","article-title":"Prevalence and Characteristics of Hip Involvement in Spondyloarthritis: A Single-Centre Observational Study of 275 Patients","volume":"30","author":"Burki","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04466-9","article-title":"Clinical and MRI Response to Dose Reduction of an Etanercept-Biosimilar for Hip Arthritis in Patients With Ankylosing Spondylitis: An Observational, Retrospective Cohort Study","volume":"38","author":"Huang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"106927","DOI":"10.1016\/j.intimp.2020.106927","article-title":"Long Term Inhibition of Hip Joint Damage Under Tumor Necrosis Factor-Alpha Inhibitors in Spondyloarthritis","volume":"88","author":"Mahmoud","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0394632016656013","article-title":"Dose Reduction of Recombinant Human Tumor Necrosis Factor Inhibitors (Etanercept) can be Effective in Ankylosing Spondylitis Patients With Synovitis of the Hip in A Chinese Population","volume":"29","author":"Li","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802409504","article-title":"Immunohistological Features of Hip Synovitis in Ankylosing Spondylitis With Advanced Hip Involvement","volume":"38","author":"Chen","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2013.03.020","article-title":"The Application of MR Imaging in the Detection of Hip Involvement in Patients With Ankylosing Spondylitis","volume":"82","author":"Huang","year":"2013","journal-title":"Eur J Radiol"},{"key":"B28","article-title":"Predictive Factors for the Longterm Outcome of Spondyloarthropathies","volume":"21","author":"Amor","year":"1994","journal-title":"J Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216841","article-title":"Real-World Evidence of TNF Inhibition in Axial Spondyloarthritis: Can We Generalise the Results From Clinical Trials","volume":"79","author":"Jones","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.740980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T07:39:13Z","timestamp":1632901153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.740980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2021.740980"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.740980","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"article-number":"740980"}}